Business Wire

XPENG

10.3.2022 14:02:20 CET | Business Wire | Press release

Share
XPENG kicks off P5 smart EV sedan reservation in four European markets and opens XPENG Experience Store in the Netherlands

XPENG (the “Company”, NYSE: XPEV and HKEX: 9868), a leading smart mobility and technology company, today kicks off customer reservations of its third and latest production model on the market, the XPENG P5 smart EV sedan, simultaneously in Denmark, the Netherlands, Norway and Sweden. The move marks a major milestone in its European expansion plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005596/en/

XPENG today is also opening its first XPENG Experience Store in the Netherlands, its second branded showroom in Europe, following the opening of the Stockholm XPENG Experience Store in Sweden last month.

The XPENG P5 is the Company’s first model to be made available simultaneously in four European markets. The customer reservation process is fully-digitized, and accessible immediately in each of these four markets, both via the XPENG official websites in each country, and the XPENG mobile APP launched earlier this week.

“The XPENG P5’s arrival in four key European markets is a new demonstration of our commitment to Europe,” said Leon He, Vice President of XPENG. “Each new XPENG model achieves a new level of technology sophistication. The P5 brings a host of differentiated features to a new customer base in Europe, a market where we are building ourselves as a long-term player,” said Mr. He.

The XPENG P5 – Intelligence that moves you

The XPENG P5, a mid-size family sedan, is equipped with version 2.5 of XPENG’s in-house developed Advanced Driver Assistance System (XPILOT), and its intelligent in-car operating system - Xmart OS. The P5 combines the advanced level of driver assistance with superior passenger comfort and convenience. Through firmware over-the-air (OTA) upgrades, the P5 will bring new features and optimized functions to customers on a continuous basis.

The sleek aerodynamic profile of the P5 with a large panoramic canopy glass sunroof, neat fastback and unobtrusive ducktail gives it a driving range of 465 km WLTP, powered by a battery of 66 kWh capacity.

The Xmart OS provides comprehensive cockpit and interior function management, with a 12.3-inch LCD dashboard, a 15.6-inch FHD high resolution (1920 * 1080) large center display, in-car voice control capable of distinguishing between driver and passenger positions, and a library of in-car Apps to assist, inform, and entertain driver and passengers.

This intelligent cockpit management is integrated into the stylish interior fittings, with heated leatherette seats, the Xfreebreath intelligent air purification system and advanced surround sound system. Many vehicle functions can also be accessed via mobile phone remote control.

For added convenience, the P5 incorporates 26 storage compartments and a 450L large trunk, plus an additional 70L compartment underneath.

XPENG experience store starts operation in the Netherlands

Concurrently, XPENG is also opening its first experience store in the Westfield Mall of the Netherlands in Leidschendam, conveniently close to major conurbations such as Rotterdam and The Hague. As well as the XPENG P5, the XPENG smart sports sedan P7, and the prototype of its flying vehicle XPENG X2 are also on display in the Westfield Mall experience store, demonstrating the brand’s vision of future mobility and its spirit of exploration.

Customers can make online reservations for XPENG P5 from today. The test drive will be available in April 2022.

Two additional stores in the Netherlands will open later this year in collaboration with XPENG's local partner Emil Frey, and the Company plans to open more stores in major cities across the Netherlands over the next few years.

XPENG P5 Specs

Dimension

Length x Width x Height (mm)

4808mm / 1840mm / 1520mm

Wheelbase (mm)

2768mm

Seats

5

Curb Weight (kg)

1715Kg

Cargo Space

520 L

 

Performance

Type of Drive

Front-wheel drive

Battery Capacity (kWh)

66 kWh

WLTP Driving Range (km)

465 Km

 

XPILOT 2.5 (ADAS)

High-definition Millimeter Wave Radar

5

Ultrasonic Wave Sensors

12

Autonomous Driving Surround View Camera

4

Autonomous Driving High Perception Camera

9

XPILOT Safety

XPILOT Driving

XPILOT Parking

 

Xmart OS In-car Intelligent System

15.6" Central Touch Screen Display

12.3" HD Liquid Crystal Intelligent Instrument Panel

Mobile App Remote Control

"Hey XPENG" Voice Assistant

Firmware over-the-air software updates

 

Exterior

Lightsaber 3.0 LED Lights

Lightsaber 3.0 LED DRL

Panoramic Sunroof

215/55R18 Michelin Tyre

 

About XPENG

XPENG is a leading smart mobility company founded with a mission to explore and drive smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley and San Diego. In 2021, XPENG established its European headquarters in the Netherlands, and is expanding its presence in Sweden, Norway and Denmark. XPENG's smart EVs are manufactured at its fully-owned plant in Zhaoqing, Guangdong Province, China. For more information, please visit: www.heyxpeng.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye